title: [Clinical use of erythropoietin].
abstract: The introduction of recombinant human erythropoietin (RHuEPO) has dramatically changed the therapeutic approach to the anemia of chronic renal failure. Clinical studies have also demonstrated that RHuEPO is effectiveness in various non-uremic conditions, such as anemia associated with onco-hematological disorders, prematurity, HIV infection and to reduce the exposure to allogeneic blood in surgical patients. In this review, we briefly analyze the main clinical applications of RHuEPO, with particular attention to the potential complications deriving from its use.
authors.affiliation: Servizio di Immunoematologia e Trasfusione, Azienda Ospedaliera di Verona, Verona. massimo.franchini@mail.azosp.vr.it
authors.forename: Massimo
authors.initials: M
authors.lastname: Franchini
authors.forename: Giorgio
authors.initials: G
authors.lastname: Gandini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Lippi
authors.forename: Marzia
authors.initials: M
authors.lastname: De Gironcoli
authors.forename: Maurizio
authors.initials: M
authors.lastname: Cantini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Aprili
mesh_terms: D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D000751:Anemia, Neonatal / Q000188:drug therapy; D001804:Blood Transfusion, Autologous; D002648:Child; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000150:complications; D008297:Male; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000150:complications; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin